An improved radiolabelled RNA aptamer molecule for HER2 imaging in cancers

Journal of Drug Targeting

Volumn 22, Issue 2, 2014, Pages 116-122

  Varmira, Kambiz ^a   Hosseinimehr, Seyed Jalal ^a   Noaparast, Zohreh ^a   Abedi, Seyed Mohammad ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

99mTc; Aptamer; Co ligand; HER2; Specific binding

Indexed keywords

APTAMER; CHELATING AGENT; DODECYL SULFATE SODIUM; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYDRAZINO NICOTINAMIDE TECHNETIUM 99M; RNA; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NEOPLASM; NONHUMAN; OVARY CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

ANIMALS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; FEMALE; GLYCINE; HUMANS; HYDRAZINES; INDICATORS AND REAGENTS; LIGANDS; MICE; MICE, NUDE; MOLECULAR IMAGING; NIACINAMIDE; OVARIAN NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; RNA; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 84891765838     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.839688     Document Type: Article

References (31)

1. Amler LC, Wang Y, Hampton G. HER2 as a therapeutic target in ovarian cancer. In: Farghaly SA, ed. Ovarian cancer-clinical and therapeutic perspectives. Rijeka, Croatia: In Tech; 2012:289-304.
2. Santarius T, Shipley J, Brewer D, et al. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer 2010;10: 59-64.
3. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharmaceut Design 2008;14:2999-3019.
4. Cho H-S, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60.
5. Hermann T, Patel DJ. Adaptive recognition by nucleic acid aptamers. Science 2000;287:820-5.
6. Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 1999;45:1628-50.
7. Song KM, Lee S, Ban C. Aptamers and their biological applications. Sensors 2012;12:612-31.
8. Bast Jr RC, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncology 2001;19:1865-78.
9. Engfeldt T, Orlova A, Tran T, et al. Imaging of HER2-expressing tumours using a synthetic affibody molecule containing the Tc-99m-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 2007;34:722-33.
10. Hnatowich DJ, Mardirossian G, Rusckowski M, et al. Directly and indirectly technetium-99m-labeled antibodies-a comparison of in vitro and animal in vivo properties. J Nucl Med 1993;34:109-19.
11. King R, Surfraz MB, Finucane C, et al. 99mTc-HYNIC-gastrin peptides: assisted coordination of 99mTc by amino acid side chains results in improved performance both in vitro and in vivo. J Nucl Med 2009;50:591-8.
12. Fu P, Shen B, Zhao C, et al. Molecular imaging of MDM2 messenger RNA with 99mTc-labeled antisense oligonucleotides in experimental human breast cancer xenografts. J Nucl Med 2010;51: 1805-12.
13. Decristoforo C, Mather SJ. 99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution. Nucl Med Biol 1999;26:389-96.
14. Decristoforo C, Mather SJ. Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence. Eur J Nucl Med 1999;26:869-76.
15. Hernandez-Cairo A, Perera-Pintado A, Prats-Capote A, et al. Comparative study of the biodistribution of (99m)Tc-HYNIC-Lys3-Bombesin obtained with the EDDA/tricine and NA/tricine as coligands. Rev Esp Med Nucl Imagen Mol 2012;31:61-5.
16. Varmira K, Hosseinimehr SJ, Noaparast Z, Abedi SM. An HER2-targeted RNA aptamer molecule labeled with 99mTc for singlephoton imaging in malignant tumors. Nucl Med Biol 2013. [Epub ahead of print]. doi: 10.1016/j.nucmedbio. 2013.07.004.
17. Persson M, Tolmachev V, Andersson K, et al. [1977] Lupertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging 2005;32: 1457-62.
18. Ruckman J, Green LS, Beeson J, et al. 20-Fluoropyrimidine RNAbased aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998;273:20556-67.
19. Dupont DM, Madsen JB, Hartmann RK, et al. Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding. RNA 2010;16:2360-9.
20. Tolmachev V, Stone-Elander S, Orlova A, et al. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol 2010;11:992-1000.
21. Wallberg H, Orlova A, Altai M, et al. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. J Nucl Med 2011;52:461-9.
22. Goldstein R, Sosabowski J, Vigor K, et al. Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer. Expert Rev Anticancer Ther 2013;13:359-73.
23. Nayak TK, Bernardo M, Milenic DE, et al. Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1-and HER2-targeted radiolabeled antibodies. Radiology 2013;267: 173-82.
24. King RC, Surfraz MB, Biagini SC, et al. How do HYNICconjugated peptides bind technetium? Insights from LC-MS and stability studies. Dalton Trans 2007;43:4998-5007.
25. Liu N, Ding H, Zhu Z, et al. Radiolabeling small RNA with technetium-99m for visualizing cellular delivery and mouse biodistribution. Nucl Med Biol 2007;34:399-404.
26. Decristoforo C, Melendez-Alafort L, Sosabowski JK, et al. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111Inoctreotide. J Nucl Med 2000;41:1114-19.
27. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367: 1783-91.
28. Weinberg WC, Frazier-Jessen MR, Wu WJ, et al. Development and regulation of monoclonal antibody products: challenges and opportunities. Cancer Metastasis Rev 2005;24:569-84.
29. Samaranayake H, Wirth T, Schenkwein D, et al. Challenges in monoclonal antibody-based therapies. Ann Med 2009;41:322-31.
30. Lub-de Hooge MN, Kosterink JG, Perik PJ, et al. Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol 2004; 143:99-106.
31. Hosseinimehr SJ, Tolmachev V, Orlova A. Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. Drug Discov Today 2012;17: 1224-32.